• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

配体结合和激活 PPARγ 的结构机制。

Structural mechanism underlying ligand binding and activation of PPARγ.

机构信息

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, Jupiter, FL 33458, USA.

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, Jupiter, FL 33458, USA; Department of Molecular Medicine, The Scripps Research Institute, Jupiter, FL 33458, USA.

出版信息

Structure. 2021 Sep 2;29(9):940-950.e4. doi: 10.1016/j.str.2021.02.006. Epub 2021 Mar 12.

DOI:10.1016/j.str.2021.02.006
PMID:33713599
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8418994/
Abstract

Ligands bind to an occluded orthosteric ligand-binding pocket within the nuclear receptor ligand-binding domain. Molecular simulations have revealed theoretical ligand entry/exit pathways to the orthosteric pocket; however, it remains unclear whether ligand binding proceeds through induced fit or conformational selection mechanisms. Here, using nuclear magnetic resonance spectroscopy, isothermal titration calorimetry, and surface plasmon resonance analysis, we provide evidence that structurally distinct agonists bind peroxisome proliferator-activated receptor γ (PPARγ) via a two-step induced fit mechanism involving an initial fast kinetic step followed by a slow conformational change. The agonist encounter complex binding pose is suggested in crystal structures where ligands bind to a surface pore suggested as a ligand entry site in molecular simulations. Our findings suggest an activation mechanism for PPARγ whereby agonist binding occurs through an initial encounter complex followed by a transition of the ligand into the final binding pose within the orthosteric pocket, inducing a transcriptionally active conformation.

摘要

配体结合到核受体配体结合域内的封闭的变构配体结合口袋。分子模拟已经揭示了进入变构口袋的理论配体进入/退出途径;然而,配体结合是通过诱导契合还是构象选择机制进行,目前仍不清楚。在这里,我们使用核磁共振波谱、等温滴定量热法和表面等离子体共振分析,提供了结构不同的激动剂通过两步诱导契合机制结合过氧化物酶体增殖物激活受体γ(PPARγ)的证据,该机制涉及初始快速动力学步骤,随后是缓慢的构象变化。在晶体结构中,配体结合到一个表面孔中,在分子模拟中,该表面孔被认为是配体进入位点,提出了激动剂结合复合物的结合构象。我们的发现为 PPARγ 的激活机制提供了线索,即激动剂结合是通过初始的结合复合物发生的,然后配体在变构口袋内转变为最终的结合构象,诱导出转录活性构象。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3544/8418994/787547328947/nihms-1679723-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3544/8418994/23491fcd5a73/nihms-1679723-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3544/8418994/98f07aa03135/nihms-1679723-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3544/8418994/717239030e19/nihms-1679723-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3544/8418994/a55cc5d7681e/nihms-1679723-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3544/8418994/2a91fc764e4d/nihms-1679723-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3544/8418994/dc261ac53989/nihms-1679723-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3544/8418994/787547328947/nihms-1679723-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3544/8418994/23491fcd5a73/nihms-1679723-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3544/8418994/98f07aa03135/nihms-1679723-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3544/8418994/717239030e19/nihms-1679723-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3544/8418994/a55cc5d7681e/nihms-1679723-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3544/8418994/2a91fc764e4d/nihms-1679723-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3544/8418994/dc261ac53989/nihms-1679723-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3544/8418994/787547328947/nihms-1679723-f0008.jpg

相似文献

1
Structural mechanism underlying ligand binding and activation of PPARγ.配体结合和激活 PPARγ 的结构机制。
Structure. 2021 Sep 2;29(9):940-950.e4. doi: 10.1016/j.str.2021.02.006. Epub 2021 Mar 12.
2
Cooperative cobinding of synthetic and natural ligands to the nuclear receptor PPARγ.合成配体和天然配体与核受体 PPARγ 的协同结合。
Elife. 2018 Dec 21;7:e43320. doi: 10.7554/eLife.43320.
3
Defining a conformational ensemble that directs activation of PPARγ.定义一个构象集合,指导 PPARγ 的激活。
Nat Commun. 2018 May 4;9(1):1794. doi: 10.1038/s41467-018-04176-x.
4
A molecular switch regulating transcriptional repression and activation of PPARγ.一种调控 PPARγ 转录抑制和激活的分子开关。
Nat Commun. 2020 Feb 19;11(1):956. doi: 10.1038/s41467-020-14750-x.
5
Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism.配体和受体动力学有助于解释 PPARγ 激动作用的递呈梯度机制。
Structure. 2012 Jan 11;20(1):139-50. doi: 10.1016/j.str.2011.10.018.
6
Ligand entry pathways in the ligand binding domain of PPARγ receptor.配体进入 PPARγ 受体配体结合域的途径。
FEBS Lett. 2011 Aug 19;585(16):2599-603. doi: 10.1016/j.febslet.2011.07.014. Epub 2011 Jul 26.
7
Agonism activities of lyso-phosphatidylcholines (LPC) Ligands binding to peroxisome proliferator-activated receptor gamma (PPARγ).溶血磷脂酰胆碱 (LPC) 配体与过氧化物酶体增殖物激活受体 γ (PPARγ) 结合的激动作用活性。
J Biomol Struct Dyn. 2020 Feb;38(2):398-409. doi: 10.1080/07391102.2019.1577175. Epub 2019 Apr 26.
8
Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.人源过氧化物酶体增殖物激活受体 δ(PPAR-δ)选择性配体结合的结构见解。
PLoS One. 2012;7(5):e33643. doi: 10.1371/journal.pone.0033643. Epub 2012 May 11.
9
Modification of the Orthosteric PPARγ Covalent Antagonist Scaffold Yields an Improved Dual-Site Allosteric Inhibitor.正构PPARγ共价拮抗剂支架的修饰产生了一种改进的双位点变构抑制剂。
ACS Chem Biol. 2017 Apr 21;12(4):969-978. doi: 10.1021/acschembio.6b01015. Epub 2017 Feb 16.
10
Quantitative structural assessment of graded receptor agonism.定量结构评估分级受体激动剂。
Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22179-22188. doi: 10.1073/pnas.1909016116. Epub 2019 Oct 14.

引用本文的文献

1
Discovery of a novel binding pocket in PPARγ for partial agonists: structure-based virtual screening identifies ginsenoside Rg5 as a partial agonist promoting beige adipogenesis.发现过氧化物酶体增殖物激活受体γ(PPARγ)中一个用于部分激动剂的新型结合口袋:基于结构的虚拟筛选鉴定人参皂苷Rg5为促进米色脂肪生成的部分激动剂。
Front Chem. 2025 May 8;13:1579445. doi: 10.3389/fchem.2025.1579445. eCollection 2025.
2
From Apo to Ligand-Bound: Unraveling PPARγ-LBD Conformational Shifts via Advanced Molecular Dynamics.从脱辅基状态到配体结合状态:通过高级分子动力学解析PPARγ配体结合域的构象转变
ACS Omega. 2025 Feb 17;10(13):13303-13318. doi: 10.1021/acsomega.4c11128. eCollection 2025 Apr 8.
3

本文引用的文献

1
Dynamic allosteric communication pathway directing differential activation of the glucocorticoid receptor.指导糖皮质激素受体差异激活的动态变构通讯途径
Sci Adv. 2020 Jul 17;6(29):eabb5277. doi: 10.1126/sciadv.abb5277. eCollection 2020 Jul.
2
Protein-ligand binding with the coarse-grained Martini model.蛋白-配体与粗粒化 Martini 模型的结合。
Nat Commun. 2020 Jul 24;11(1):3714. doi: 10.1038/s41467-020-17437-5.
3
A molecular switch regulating transcriptional repression and activation of PPARγ.一种调控 PPARγ 转录抑制和激活的分子开关。
Ligand efficacy shifts a nuclear receptor conformational ensemble between transcriptionally active and repressive states.
配体效力使核受体构象集合在转录活性状态和抑制状态之间转变。
Nat Commun. 2025 Feb 28;16(1):2065. doi: 10.1038/s41467-025-57325-4.
4
Modulation of Protein-Protein Interactions with Molecular Glues in a Synthetic Condensate Platform.在合成凝聚物平台中利用分子胶对蛋白质-蛋白质相互作用进行调控。
J Am Chem Soc. 2025 Feb 12;147(6):5386-5397. doi: 10.1021/jacs.4c17567. Epub 2025 Jan 28.
5
Unanticipated mechanisms of covalent inhibitor and synthetic ligand cobinding to PPARγ.意想不到的共价抑制剂和合成配体与 PPARγ 共结合的机制。
Elife. 2024 Nov 18;13:RP99782. doi: 10.7554/eLife.99782.
6
Agonists of the Nuclear Receptor PPARγ Can Produce Biased Signaling.核受体 PPARγ 的激动剂可产生偏向性信号。
Mol Pharmacol. 2024 Nov 18;106(6):309-318. doi: 10.1124/molpharm.124.000992.
7
Cladosporols and PPARγ: Same Gun, Same Bullet, More Targets.枝孢菌素和过氧化物酶体增殖物激活受体 γ:同一把枪,同样的子弹,更多的目标。
Biomolecules. 2024 Aug 13;14(8):998. doi: 10.3390/biom14080998.
8
Unanticipated mechanisms of covalent inhibitor and synthetic ligand cobinding to PPARγ.共价抑制剂与合成配体共结合至PPARγ的意外机制。
bioRxiv. 2024 Sep 12:2024.05.15.594037. doi: 10.1101/2024.05.15.594037.
9
Ligand efficacy shifts a nuclear receptor conformational ensemble between transcriptionally active and repressive states.配体效力使核受体构象集合在转录活性状态和抑制状态之间转变。
bioRxiv. 2024 Apr 24:2024.04.23.590805. doi: 10.1101/2024.04.23.590805.
10
PPARγ Modulators in Lung Cancer: Molecular Mechanisms, Clinical Prospects, and Challenges.PPARγ 调节剂在肺癌中的作用:分子机制、临床前景和挑战。
Biomolecules. 2024 Feb 4;14(2):190. doi: 10.3390/biom14020190.
Nat Commun. 2020 Feb 19;11(1):956. doi: 10.1038/s41467-020-14750-x.
4
Quantitative structural assessment of graded receptor agonism.定量结构评估分级受体激动剂。
Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22179-22188. doi: 10.1073/pnas.1909016116. Epub 2019 Oct 14.
5
Structural Basis for the Regulation of PPARγ Activity by Imatinib.伊马替尼调控 PPARγ 活性的结构基础。
Molecules. 2019 Oct 1;24(19):3562. doi: 10.3390/molecules24193562.
6
Molecular tuning of farnesoid X receptor partial agonism.法尼醇 X 受体部分激动剂的分子调节。
Nat Commun. 2019 Jul 2;10(1):2915. doi: 10.1038/s41467-019-10853-2.
7
Ligand Pathways in Nuclear Receptors.核受体中的配体途径。
J Chem Inf Model. 2019 Jul 22;59(7):3100-3109. doi: 10.1021/acs.jcim.9b00360. Epub 2019 Jul 11.
8
Obtaining Crystals of PPARγ Ligand Binding Domain Bound to Small Molecules.获取与小分子结合的过氧化物酶体增殖物激活受体γ配体结合域的晶体。
Methods Mol Biol. 2019;1966:253-260. doi: 10.1007/978-1-4939-9195-2_21.
9
Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone.抗糖尿病药物 PPARγ 药物吡格列酮主要体内代谢物显示效力和效力改变的结构基础。
J Med Chem. 2019 Feb 28;62(4):2008-2023. doi: 10.1021/acs.jmedchem.8b01573. Epub 2019 Feb 7.
10
Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation.鉴定出首个能够与 PPARγ 的经典和替代结合位点结合并抑制其 Cdk5 介导的磷酸化的 PPARα/γ 双重激动剂。
J Med Chem. 2018 Sep 27;61(18):8282-8298. doi: 10.1021/acs.jmedchem.8b00835. Epub 2018 Sep 18.